Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more
Regencell Bioscience Holdings Ltd (RGC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.243x
Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) has a cash flow conversion efficiency ratio of -0.243x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.00 Million) by net assets ($8.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Regencell Bioscience Holdings Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Regencell Bioscience Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regencell Bioscience Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hiecise Precision Equipment Co Ltd
SHE:300809
|
0.040x |
|
ICHOR HLDGS LTD DL-0001
F:4IH
|
N/A |
|
Beken Corp
SHG:603068
|
0.014x |
|
Guangxi Wuzhou Communications Co Ltd
SHG:600368
|
0.040x |
|
Vina Concha To
SN:CONCHATORO
|
-0.033x |
|
DYNAGREEN EN.PR.GR.H YC 1
F:DYN
|
N/A |
|
Intracom Constructions Societe Anonyme Technical and Steel Constructions
AT:INKAT
|
-0.125x |
|
Zhejiang Shengyang Science
SHG:603703
|
0.010x |
Annual Cash Flow Conversion Efficiency for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Regencell Bioscience Holdings Ltd from 2003 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $4.86 Million | $-3.11 Million | -0.641x | -31.57% |
| 2024-06-30 | $8.22 Million | $-4.00 Million | -0.487x | -17.62% |
| 2023-06-30 | $11.99 Million | $-4.96 Million | -0.414x | -34.24% |
| 2022-06-30 | $17.08 Million | $-5.27 Million | -0.308x | -260.65% |
| 2021-06-30 | $-4.00 Million | $-767.31K | 0.192x | -29.97% |
| 2020-06-30 | $-2.65 Million | $-726.57K | 0.274x | +28.88% |
| 2019-06-30 | $-1.84 Million | $-390.99K | 0.213x | +144.40% |
| 2018-06-30 | $-855.80 Million | $409.90 Million | -0.479x | +2.12% |
| 2017-06-30 | $-838.90 Million | $410.50 Million | -0.489x | +1.14% |
| 2016-06-30 | $-877.60 Million | $434.40 Million | -0.495x | -26.87% |
| 2015-06-30 | $-894.80 Million | $349.10 Million | -0.390x | +19.77% |
| 2014-06-30 | $-713.40 Million | $346.90 Million | -0.486x | +2.24% |
| 2013-06-30 | $-696.80 Million | $346.60 Million | -0.497x | +19.58% |
| 2012-06-30 | $-570.90 Million | $353.10 Million | -0.618x | -16.90% |
| 2011-06-30 | $-490.30 Million | $259.40 Million | -0.529x | +68.20% |
| 2010-06-30 | $-246.90 Million | $410.80 Million | -1.664x | -49.13% |
| 2009-06-30 | $-242.00 Million | $270.00 Million | -1.116x | +83.40% |
| 2008-06-30 | $-119.00 Million | $800.00 Million | -6.723x | +53.56% |
| 2007-06-30 | $-21.00 Million | $304.00 Million | -14.476x | -216.26% |
| 2006-06-30 | $31.00 Million | $386.00 Million | 12.452x | +128.44% |
| 2005-06-30 | $71.00 Million | $387.00 Million | 5.451x | +813.79% |
| 2004-06-30 | $798.00 Million | $476.00 Million | 0.596x | +103.73% |
| 2003-06-30 | $1.27 Billion | $373.00 Million | 0.293x | -- |